Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 8/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026520 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL799686 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL799668 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL20345667 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL10324251 | 1.00 | PDE4D (0.46) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL15617563 | 0.89 | PDE4D (0.35) | PDE4DPDE3ASLC29A1 | |
| SCHEMBL12758154 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL14073159 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL15334647 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A | |
| SCHEMBL14262807 | 0.88 | PDE4D (0.37) | PDE4DPDE3ASLC29A1CDAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | PDE4D 3186/4885PDE3A 2116/4885SLC29A1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.